Amisulpride - A new benzamide antipsychotic of the second generation;Souborné referáty: Amisulprid- Nové benzamidové antipsychotikum II. Generace (Souhrnné sdelení)

Ceska a Slovenska Psychiatrie

Volumn 96, Issue 8, 2000, Pages 411-415

  Ceskova E ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Amisulpride; Antipsychotics of the second generation; Deficiency schizophrenia; Pharmacological profile; Side effects

Indexed keywords

AMISULPRIDE; BENZAMIDE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

CLINICAL FEATURE; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG BINDING SITE; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; DRUG SAFETY; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIMBIC SYSTEM; POSTSYNAPTIC INHIBITION; PRESYNAPTIC INHIBITION; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SYMPTOM; TREATMENT OUTCOME;

EID: 17144474185     PISSN: 12120383     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Treatment of negative symptoms in schizophrenia with amisulpride
2. Evaluation de l'efficacité et de la tolerance de lamisulpride dnas le traitement des psychoses schizophrénigues
3. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
4. A comparative double-blind trial of amisulpride versus haloperidol in the treatment of acute psychotic disorders
5. Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the managemenet of schizophrenia
6. Safety of amisulpride (Solian): A review of 11 clinical studies
7. The amisulpride study group: Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride
8. Amisulpride versus haloperidol in treatment of schizophrenic patients- Results of a double-blind study
9. Efficacy and safety of amisulpride versus haloperidol: A 4 month assessment
10. Olanzapine versus amisulpride and placebo in the treatment of negative symptoms and deficit states of chronic schizophrenia
11. Suicidal behaviour in amisulpride treated patients: A pooled review of 11 clinical studies
12. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
13. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia
14. Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperidol
15. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
16. Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers
17. Psychopharmacological profile of amisulpride. An antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity
18. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
19. A double blind, controlled, multicenter trial of low dose amisulpride (Solian 50) versus low dose of fluphenazine in the treatment of negative symptoms in chronic schizophrenia
20. Amisulpride Study Group: Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs. haloperidol
21. Safety profile of amisulpride in short-and long-term use
22. Treatment-emergent tardive dyskinesia in the long-term treatment of schizophrenia: A comparison of amisulpride and haloperidol
23. Amisulpride improved affective symptoms in acute schizophrenia
24. Clinical, EEG mapping and psychometric studies in negative schizophrenia: A comparative trials with amisulpride and fluphenazine
25. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity
26. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol
27. Amisulpride versus flupenthixol in schizophrenia with predominantly positive symptomatology - A double blind controlled study comparing a selective D2 like antagonist to a mixed D1-/D2-1ike antagonist